Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
Naylor
C D
CD
Bronskill
S
S
Goel
V
V
D003362:Cost-Benefit Analysis; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000191:economics / Q000627:therapeutic use; D013300:Streptokinase / Q000191:economics / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics*
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010960:Plasminogen Activators